Child-Pugh score

(redirected from Child-Turcotte-Pugh score)

Child-Pugh score

assessment scale used in clinical staging of cirrhosis.
A scoring system used to assess the prognosis of chronic liver disease, mainly cirrhosis, to predict operative mortality, the need for titrate therapy and the need for liver transplantation

Child-Pugh score

Hepatology A scoring system used in Pts undergoing TIPS, which describes a range of severity of liver disease. See TIPS.
References in periodicals archive ?
KEYWORDS: Biochemical parameters, Child-Turcotte-Pugh score, Hepatitis C, Liver cirrhosis, Malnutrition.
Liver cirrhosis had been documented by history, clinical findings, laboratory parameters (complete blood picture, liver function test and coagulation profile) and imaging (ultrasonographic evidence of shrunken liver, coarse echotexture, splenomegaly or ascites).11 Cirrhosis severity was scored according to Child-Turcotte-Pugh score (CTP) A to C.12 History and examination were carried out to assess ascites, as well as to confirm inclusion and exclusion criteria.
CTP-A: Child-Turcotte-Pugh score A, CTP-B+C: Child-Turcotte-Pugh score B and C, HCV: hepatitis C virus, NASH: nonalcoholic steatohepatitis, PSC: primary sclerosing cholangitis, PBC: primary biliary cirrhosis, EV: esophageal varices, PHG: portal hypertension gastropathy, GV: gastric varices, PHE: portal hypertension enteropathy, and OR: odd ratio.
KEY WORDS: chronic liver disease; viral hepatitis; serum markers; modified Child-Turcotte-Pugh score.
The implementation of the new liver allocation system in our state has required a change in the disease severity score, with minimal weighting being allocated to the waiting time compared with the previous system that was based on the Child-Turcotte-Pugh score and on the waiting time.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis.
Child-Turcotte-Pugh score varied from A5 to C11; most were classified as Child B (58%).
With respect to cirrhosis with complications, a placebo-controlled randomized trial showed a clinically relevant improvement in the Child-Turcotte-Pugh score and a borderline significant reduction in the incidence of liver cancer with oral antiviral therapy.
With colchicine, 9% of patients showed improvement on their Child-Turcotte-Pugh score during follow-up, 35% showed no change, and 56% showed disease progression.
Typically, the Child-Turcotte-Pugh score is used most often to predict survival in patients being considered for resection, said Dr.
However, slightly more patients on adefovir (67%) showed improvement, or no worsening, in their Child-Turcotte-Pugh scores, compared with 61% of those on entecavir.
The Model for End-Stage Liver Disease (MELD), established in 2002, replaced the previous method of stratifying patients for transplant, which was based on waiting list time, Child-Turcotte-Pugh scores, and hospital status (e.g., intensive care vs.